The Genitourinary Cancers Program (GU) is a multidisciplinary research program that includes 17 members from 6 RPCI departments. The overall goal of the GU Program is to translate basic science findings into the clinical setting by identifying novel therapeutic targets and strategies for the prevention and treatment of patients with prostate, kidney and bladder cancer. There are three overarching themes for the GU Program: Theme 1: Genetic and epigenetic signatures;Theme 2: Tumor microenvironment;Theme 3: Novel therapeutic strategies. Program membership spans the breadth of genitourinary cancer and studies highlight investigations on the androgen receptor in prostate cancer, cellular targets in endothelial cells and tumor stem cells in prostate and kidney cancer, new target identification by genetic and epigenetic profiling in renal cell carcinoma and bladder cancer, and the role of vitamin D and broccoli sprout extracts in preclinical and clinical studies for therapy and prevention, respectively in bladder cancer. In addition, the program includes a robust portfolio of clinical studies based on research in the GU program. The GU Program is led by Roberto Pili MD, who has expertise in translational and clinical research in GU malignancies. Dr. Pili's leadership efforts focus on translating novel therapeutic strategies based on preclinical models of prostate, kidney and bladder cancer into clinical testing. The strength of the translational capability of the GU Program is documented by the number of investigator-initiated clinical trials (14) currently accruing across the three disease types. Since the last submission, GU members have authored 365 publications;19% inter-programmatic collaboration, and 32% intra-programmatic. Current annual total peer-reviewed Program funding is $10.3M, of which $9.0M is NCI, and the total extramural research funding is $11.9M. Weekly seminars, annual research retreats and symposiums foster internal and external collaborations. GU Program members use 13 of the 14 CCSG shared resources and their laboratories contribute to the mentoring of more than twenty pre-doctoral and post-doctoral students from the RPCI Graduate Division. Future plans include expanding the genetic and epigenetic characterization of drug resistant phenotypes across genitourinary cancers and developing novel multimodality, rational combination strategies for the treatment of prostate, kidney and bladder cancer.

Public Health Relevance

of the GU Program mission stems from the strong translational emphasis of all the research projects focused on the identification and testing of new therapies for the prevention and treatment of prostate, kidney and bladder cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22
Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77
Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65
Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77
Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70
Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59

Showing the most recent 10 out of 517 publications